A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver
A Phase I Dose Escalation Tolerability Study of ThermoDox™ (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) of Primary and Metastatic Tumors of the Liver
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Manhasset, New York, United States, 11030
- Northshore Hospital - Long Island Jewish Health System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be 18 years of age or older.
- Are willing to sign an informed consent form, indicating that they are aware of the investigational nature of this study that is in keeping with the policies of the institution.
- Have a diagnosis of metastatic liver cancer (MLC) or primary hepatocellular cancer (HCC) confined to the liver.
- Be an appropriate candidate for receiving RFA as a medically indicated treatment.
- Have an echocardiogram revealing an Ejection Fraction (EF) ≥ 50%.
- Willing to return to the study site for their imaging scans.
- Have life expectancy of ≥ 3 months.
- Have ECOG performance status of 0-2 or Karnofsky score of 60-100% (see Appendix II).
- Have no more than Childs-Pugh Class B liver disease.
- Subjects must have no prior doxorubicin exposure.
- No single lesion should be > 7 cm in maximum diameter.
- Subjects must agree to receive no other systemic therapy from the time of study enrollment until a minimum of 21 days after their ThermoDox infusion
Exclusion Criteria:
- Have serious medical illnesses including, but not limited to, congestive heart failure, myocardial infarction or cerebral vascular accident within the last six months, or life threatening cardiac arrhythmias.
- Are pregnant or breast feeding. In women of childbearing potential, a negative pregnancy test (serum) is required at baseline, 1 month and each 3 month follow-up visit.
- Are not practicing an acceptable form of birth control (i.e. diaphragm, cervical cap, condom, surgical sterility or birth control pills. Woman whose husband has undergone a vasectomy must use a second form of birth control).
- Have known serious allergic reactions (anaphylaxis) to any of the drugs or liposomal components or imaging agents to be used in this study.
- Have portal or hepatic vein invasion/thrombosis.
- Have PT or PTT > 1.5 times the institution's upper normal limit (UNL), except in subjects who are therapeutically anticoagulated for non-related medical conditions such as atrial fibrillation.
- Have platelet count > 75,000/mm3, absolute neutrophil count > 1500/mm3, or Hgb > 10 (unless the hemoglobin value has been stable, the subject is cardiovascularly stable, asymptomatic and judged able to withstand the RFA
- Have serum creatinine ≤ 2.0 mg/dl (or calculated CrCl ≤ 60mL/min).
- Have contraindications to receiving doxorubicin HCl.
- Are being treated with other investigational agents (within a minimum of 30 days or 5 half-lives of the investigational agent).
- Have other concurrent malignancy (subjects with benign or non aggressive malignant tumors-e.g.: squamous cell cancer of the skin-may be included), evidence of extrahepatic cancer from their primary malignancy, or ongoing, medically significant active infection.
- Documented HIV positive.
- NYHA class III or IV cardiovascular disease or LVEF < 50%.
- Evidence of hemachromatosis.
- Are on any of the medications listed in section 6.3, which could have an adverse effect when combined with the study drug, and who cannot stop the medication for the duration of the study and 30 days beyond the treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ThermoDox + RFA
ThermoDox administered as single dose intravenously over 30 minutes in combination with radiofrequency ablation.
Dose is determined by dose cohort patient enters study.
|
15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000.
Administered as single dose intravenously over 30 minutes.
Dose is determined by dose cohort patient enters study.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine the maximum tolerated dose (MTD) of systemically delivered, heat-activated liposome encapsulated doxorubicin (ThermoDox) in combination with radiofrequency ablation (RFA) of liver neoplasms.
Time Frame: 1 month
|
1 month
|
|
To test alternative infusion reaction prophylaxis regimens
Time Frame: 48 hours
|
48 hours
|
|
To assess the safety of ThermoDox plus RFA afer administration of potential multiple cycles
Time Frame: 3 years
|
3 years
|
|
To determine the Pharmacokinetics (PK) of ThermoDox
Time Frame: 48 hours
|
48 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To document any anti-tumor activity and assess recurrences.
Time Frame: 3 years
|
3 years
|
|
To measure post ablation lesion volume.
Time Frame: 1 month
|
1 month
|
|
To determine the cardiotoxicity of ThermoDox through enhanced ECG monitoring.
Time Frame: 48 hours
|
48 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 104-06-101-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.